Samsung Biologics Signs Pharmaceutical Contract Manufacturing Agreement Worth 439.4 Billion KRW
[Asia Economy Reporter Kang Nahum] Samsung Biologics announced on the 5th that it has signed a contract for contract manufacturing of pharmaceuticals worth 439.37099 billion KRW with the British pharmaceutical company GSK (GlaxoSmithKline Trading Services Limited).
Hot Picks Today
"Two Eggs for Breakfast, My Protein" The Betrayal of Soft-Boiled Eggs...In July, Always Eat Them Hard-Boiled
- "I Spent 28 Billion Won and Even Received My Son's Plasma to Avoid Aging... But Was Diagnosed with an Incurable Disease"
- Samsung Electronics to Sell KRW 344.5 Billion in Treasury Shares for DX Division Employee Compensation
- "Severity of Social Harm" - Local Official Sentenced to Death in China for Accepting 500 Billion Won in Bribes Over 30 Years
- "Do Not Mess with Her" Warning... Belgium Steps Up Against Trump’s Continued Mockery
This corresponds to 62.62% of the company's recent sales. The contract period is from April 9 to December 31, 2022.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
